BMY as of Oct 31 · 12:23 ET
BMYNYSEPharmaceutical Preparations
Bristol Myers Squibb Co · Brief
Next report
96 days
Feb 4 · before openest.Q4 FY26
Expected move
No implied move.
3 of 8≥ implied
- avg implied
- ±4.1%
- avg realized
- ±3.7%
Feb 6 '25±4.7%▼−3.84%×0.82
Apr 24 '25±4.4%▲+0.33%×0.07
Jul 31 '25±4.2%▼−5.81%×1.38
Oct 30 '25±4.2%▲+7.09%×1.68
Feb 5 '26±3.8%▲+3.30%×0.87
Q1 FY26±4.1%▲+5.21%×1.28
Q2 FY26±3.7%▲+2.79%×0.75
Q3 FY26±3.6%▲+1.35%×0.38
quarterimplied−10%0+10%realized×
Q3 FY26±3.6%▲+1.35%×0.38
Q2 FY26±3.7%▲+2.79%×0.75
Q1 FY26±4.1%▲+5.21%×1.28
Feb '26±3.8%▲+3.30%×0.87
Oct '25±4.2%▲+7.09%×1.68
Jul '25±4.2%▼−5.81%×1.38
2 older reports
Apr '25±4.4%▲+0.33%×0.07
Feb '25±4.7%▼−3.84%×0.82
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close
Bull & bear
Feb 4 report · est.—
Linked exposure
BMY report sessionNo linked exposure.
Your note
privateThesis 0 · Decisions 0 · Observations 0
No thesis.